Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Indivior Pharmaceuticals (INDV) Invested Capital (2021 - 2025)

Indivior Pharmaceuticals (INDV) has 5 years of Invested Capital data on record, last reported at -$69.0 million in Q4 2025.

  • For Q4 2025, Invested Capital fell 1625.0% year-over-year to -$69.0 million; the TTM value through Dec 2025 reached -$69.0 million, down 1625.0%, while the annual FY2025 figure was -$69.0 million, 1625.0% down from the prior year.
  • Invested Capital reached -$69.0 million in Q4 2025 per INDV's latest filing, up from -$189.0 million in the prior quarter.
  • Across five years, Invested Capital topped out at $437.0 million in Q4 2021 and bottomed at -$310.0 million in Q3 2024.
  • Average Invested Capital over 5 years is -$94.5 million, with a median of -$161.0 million recorded in 2024.
  • Peak YoY movement for Invested Capital: surged 566.67% in 2023, then tumbled 1625.0% in 2025.
  • A 5-year view of Invested Capital shows it stood at $437.0 million in 2021, then tumbled by 102.75% to -$12.0 million in 2022, then soared by 566.67% to $56.0 million in 2023, then plummeted by 107.14% to -$4.0 million in 2024, then crashed by 1625.0% to -$69.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Invested Capital were -$69.0 million in Q4 2025, -$189.0 million in Q3 2025, and -$239.0 million in Q2 2025.